Filing Flows › Theravance Biopharma (TBPH) › Q2 2026 › vs Q1 2026
Theravance Biopharma (TBPH) Q2 2026 vs Q1 2026 (quarter over quarter)
Theravance Biopharma's revenue rose $3.0M (+17%) from $17.7M in Q1 2026 to $20.7M in Q2 2026.
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $20.7M | $17.7M | $3.0M | +17% |
| Other income, net | $3.5M | $3.0M | $473K | +16% |
| Net loss | $5.9M | $4.9M | $965K | +20% |
| Costs & expenses | $30.1M | $27.2M | $2.9M | +11% |
| Operating costs | $29.0M | $27.2M | $1.8M | +7% |
| Income tax | $1.1M | −$1.5M | $2.6M | — |
| Research & development | $4.7M | $5.8M | −$1.1M | -19% |
| SG&A | $14.2M | $17.7M | −$3.5M | -20% |
| Other operating costs | $10.1M | $3.6M | $6.5M | +179% |
| Operating cash sources | $13.0M | −$68.8M | $81.7M | — |
| Share-based compensation | $6.0M | $4.5M | $1.5M | +33% |
| Cash used in operations | $7.0M | −$73.3M | $80.2M | — |
| Net loss absorbed | $5.9M | $4.9M | $965K | +20% |
| Working capital & other | $7.1M | −$73.7M | $80.8M | — |
Questions
How much did Theravance Biopharma's revenue grow quarter over quarter in Q2 2026?
Theravance Biopharma's revenue rose $3.0M (+17%) from $17.7M in Q1 2026 to $20.7M in Q2 2026.